News Tonight Africa | UPDATE 2-FDA staff review recommends against Novartis heart failure drug Reuters "We recommend that serelaxin not be approved at this time because there is insufficient evidence to support the proposed indication to "improve the symptoms of acute heart failure through reduction of the rate of worsening of heart failure," the ... FDA Reviewers Recommend Against Approval For Novartis Heart Failure Drug FDA Staff Recommends Rejection of Novartis Heart-Failure Drug More bad news for Novartis on heart failure candidate |
